Molecular Design of Conjugated Small Molecule Nanoparticles for Synergistically Enhanced PTT/PDT

HighlightsA donor-acceptor-donor (D-A-D) conjugated small molecule IID-ThTPA with narrow singlet-triplet energy gap is synthesized acceptor-oriented molecular design.viaIID-ThTPA nanoparticles exhibit not only competitive photothermal conversion efficiency (35.4%), but also a dramatically high singlet oxygen quantum yield (84.0%).IID-ThTPA nanoparticles enable superior cooperative tumor PTT/PDT eradicating capability both in vitro and in vivo. AbstractSimultaneous photothermal therapy (PTT) and photodynamic therapy (PDT) is beneficial for enhanced cancer therapy due to the synergistic effect. Conventional materials developed for synergistic PTT/PDT are generally multicomponent agents that need complicated preparation procedures and be activated by multiple laser sources. The emerging monocomponent diketopyrrolopyrrole (DPP)-based conjugated small molecular agents enable dual PTT/PDT under a single laser irradiation, but suffer from low singlet oxygen quantum yield, which severely restricts the therapeutic efficacy. Herein, we report acceptor-oriented molecular design of a donor-acceptor-donor (D-A-D) conjugated small molecule (IID-ThTPA)-based phototheranostic agent, with isoindigo (IID) as selective acceptor and triphenylamine (TPA) as donor. The strong D-A strength and narrow singlet-triplet energy gap endow IID-ThTPA nanoparticles (IID-ThTPA NPs) high mass extinction coefficient (18.2 L g(-1) cm(-1)), competitive photothermal conversion efficiency (35.4%), and a dramatically enhanced singlet oxygen quantum yield (84.0%) comparing with previously reported monocomponent PTT/PDT agents. Such a high PTT/PDT performance of IID-ThTPA NPs achieved superior tumor cooperative eradicating capability in vitro and in vivo.